Protective Efficacy of Newcastle Disease Virus Expressing Soluble Trimeric Hemagglutinin against Highly Pathogenic H5N1 Influenza in Chickens and Mice

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Cornelissen, Lisette A H M ^a   de Leeuw, Olav S ^a   Tacken, Mirriam G ^a   Klos, Heleen C ^a   de Vries, Robert P ^b   de Boer Luijtze, Els A ^a   van Zoelen Bos, Diana J ^a   Rigter, Alan ^b   Rottier, Peter J M ^b   Moormann, Rob J M ^a,b   de Haan, Cornelis A M ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; LIVE VACCINE; NEWCASTLE DISEASE VACCINE; NEWCASTLE DISEASE VACCINE H5; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CHICKEN; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNIZATION; INFLUENZA A (H5N1); INFLUENZA VACCINATION; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PATHOGENICITY; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; START CODON; STOP CODON; TROPISM; VIRAL TROPISM; VIRION; VIRUS SHEDDING;

ANIMALS; ANTIBODY FORMATION; CHICKENS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; MICE; MICE, INBRED BALB C; NEWCASTLE DISEASE VIRUS; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN MULTIMERIZATION; RECOMBINATION, GENETIC; SOLUBILITY; TREATMENT OUTCOME; VACCINATION; VIRUS SHEDDING;

AVES; AVIAN INFLUENZA VIRUS; GALLUS GALLUS; MAMMALIA; MUS; NEWCASTLE DISEASE VIRUS;

EID: 84865492926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044447     Document Type: Article

References (45)

1. Taylor J, Weinberg R, Kawaoka Y, Webster RG, Paoletti E, (1988) Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine 6: 504-508.
2. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80: 1959-1964.
3. Luschow D, Werner O, Mettenleiter TC, Fuchs W, (2001) Protection of chickens from lethal avian influenza A virus infection by live-virus vaccination with infectious laryngotracheitis virus recombinants expressing the hemagglutinin (H5) gene. Vaccine 19: 4249-4259.
4. Wu Q, Fang L, Wu X, Li B, Luo R, et al. (2009) A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Mol Immunol 46: 2210-2217.
5. Ge J, Deng G, Wen Z, Tian G, Wang Y, et al. (2007) Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 81: 150-158.
6. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, et al. (2010) Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 84: 1489-1503.
7. Nayak B, Rout SN, Kumar S, Khalil MS, Fouda MM, et al. (2009) Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS One 4: e6509.
8. Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, et al. (2001) Recombinant Newcastle disease virus as a vaccine vector. J Virol 75: 11868-11873.
9. Park MS, Steel J, Garcia-Sastre A, Swayne D, Palese P, (2006) Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A 103: 8203-8208.
10. Swayne DE, Suarez DL, Schultz-Cherry S, Tumpey TM, King DJ, et al. (2003) Recombinant paramyxovirus type 1-avian influenza-H7 virus as a vaccine for protection of chickens against influenza and Newcastle disease. Avian Dis 47: 1047-1050.
11. Veits J, Wiesner D, Fuchs W, Hoffmann B, Granzow H, et al. (2006) Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc Natl Acad Sci U S A 103: 8197-8202.
12. Mayo MA, (2002) A summary of taxonomic changes recently approved by ICTV. Arch Virol 147: 1655-1663.
13. van Oirschot JT, (2001) Present and future of veterinary viral vaccinology: a review. Vet Q 23: 100-108.
14. Alexander DJ, Gough RE (2003) Newcastle disease, other avian paramyxoviruses and pneumovirus infections. In: Saif YM, Barnes HJ, Fadly AM, Glisson JR, McDougald LR et al., editors. Diseases of poultry. 11 ed. Ames, IA.: Iowa State University Press. 63-92.
15. Capua I, Alexander DJ, (2004) Human health implications of avian influenza viruses and paramyxoviruses. Eur J Clin Microbiol Infect Dis 23: 1-6.
16. DiNapoli JM, Yang L, Suguitan A Jr, Elankumaran S, Dorward DW, et al. (2007) Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol 81: 11560-11568.
17. Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL, (2006) Nonsegmented negative-strand viruses as vaccine vectors. J Virol 80: 10293-10306.
18. Yang L, Sanchez A, Ward JM, Murphy BR, Collins PL, et al. (2008) A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology 377: 255-264.
19. Collins PL, Bukreyev A, Murphy BR, (2008) What are the risks-hypothetical and observed-of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses? J Virol 82: 9805-9806.
20. Cornelissen LA, de Vries RP, de Boer-Luijtze EA, Rigter A, Rottier PJ, et al. (2010) A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS One 5: e10645.
21. Bosch BJ, Bodewes R, de Vries RP, Kreijtz JH, Bartelink W, et al. (2010) Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J Virol 84: 10366-10374.
22. Loeffen WL, de Vries RP, Stockhofe N, van Zoelen-Bos D, Maas R, et al. (2011) Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus. Vaccine 29: 1545-1550.
23. Weldon WC, Wang BZ, Martin MP, Koutsonanos DG, Skountzou I, et al. (2010) Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 5.
24. Antin PB, Ordahl CP, (1991) Isolation and characterization of an avian myogenic cell line. Dev Biol 143: 111-121.
25. Britton P, Green P, Kottier S, Mawditt KL, Penzes Z, et al. (1996) Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus. J Gen Virol 77 (Pt 5): 963-967.
26. Dortmans JC, Koch G, Rottier PJ, Peeters BP, (2009) Virulence of pigeon paramyxovirus type 1 does not always correlate with the cleavability of its fusion protein. J Gen Virol 90: 2746-2750.
27. Harbury PB, Zhang T, Kim PS, Alber T, (1993) A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262: 1401-1407.
28. Calain P, Roux L, (1993) The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67: 4822-4830.
29. Peeters BP, Gruijthuijsen YK, de Leeuw OS, Gielkens AL, (2000) Genome replication of Newcastle disease virus: involvement of the rule-of-six. Arch Virol 145: 1829-1845.
30. Peeters BP, de Leeuw OS, Koch G, Gielkens AL, (1999) Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73: 5001-5009.
31. Hierholzer J, Killington R (1996) Virus isolation and quantitation. In: Mahy B, Kangro H, editors. Virology methods manual. London: Academic Press. 25-46.
32. Wensvoort G, Terpstra C, Boonstra J, Bloemraad M, Van Zaane D, (1986) Production of monoclonal antibodies against swine fever virus and their use in laboratory diagnosis. Vet Microbiol 12: 101-108.
33. Council Directive 92/66/EEC of 14 July 1992 introducing Community measures for the control of Newcastle disease (1992) Office Journal of the European Communities. L260: 1-20.
34. Leenaars PP, Hendriksen CF, Angulo AF, Koedam MA, Claassen E, (1994) Evaluation of several adjuvants as alternatives to the use of Freund's adjuvant in rabbits. Vet Immunol Immunopathol 40: 225-241.
35. van der Goot JA, Koch G, de Jong MC, van Boven M, (2005) Quantification of the effect of vaccination on transmission of avian influenza (H7N7) in chickens. Proc Natl Acad Sci U S A 102: 18141-18146.
36. Nagai Y, Klenk HD, Rott R, (1976) Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology 72: 494-508.
37. Wei CJ, Xu L, Kong WP, Shi W, Canis K, et al. (2008) Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 82: 6200-6208.
38. Panda A, Huang Z, Elankumaran S, Rockemann DD, Samal SK, (2004) Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb Pathog 36: 1-10.
39. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, et al. (2006) Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444: 378-382.
40. Pillai SP, Lee CW, (2010) Species and age related differences in the type and distribution of influenza virus receptors in different tissues of chickens, ducks and turkeys. Virol J 7: 5.
41. Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, et al. (2006) Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol 80: 7469-7480.
42. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, et al. (2006) H5N1 virus attachment to lower respiratory tract. Science 312: 399.
43. Yang ZY, Wei CJ, Kong WP, Wu L, Xu L, et al. (2007) Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317: 825-828.
44. Bachmann MF, Jennings GT, (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10: 787-796.
45. Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, Cros J, Mertz SE, et al. (2006) Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 80: 1130-1139.